DRD2 and cancer: ONC201 is a first‐in‐class small molecule selective orally bioavailable dopamine D2‐like receptor (DRD2) antagonist that is in Phase I‐II clinical trials in select cancers and has been well tolerated with minimal toxicity noted in these human trials.32, 33, 34, 35